Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval of a HER2-targeted therapy
Author | Vranic, Semir |
Author | Gatalica, Zoran |
Available date | 2024-08-25T05:38:00Z |
Publication Date | 2024 |
Publication Name | Biomolecules & biomedicine |
Resource | Scopus |
ISSN | 2831090X |
Abstract | Oncologic treatment has recently undergone substantial therapeutic paradigm shifts, from classical tumor-specific and biomarker-agnostic approaches to more molecular, biomarker-specific, and tumor-agnostic. Tumor-type (histology) agnostic drugs work across cancer types and present a novel shift in precision oncology. Compared with traditional cancer therapies, this novel approach implies molecularly informed treatment strategies and enables targeted treatment regardless of tumor histology (type). Such drugs are usually utilized in small clinical cohorts with diverse tumor types sharing a common genomic event (molecular biomarker). One of the key elements of this approach is the presence of a common biomarker across many tumor types. Biomarker predicts response to the targeted drugs, as well as deciphers potential resistance mechanisms. |
Language | en |
Publisher | the Association of Basic Medical Sciences |
Subject | antineoplastic agent epidermal growth factor receptor 2 ERBB2 protein, human tumor marker drug approval drug therapy genetics human metabolism molecularly targeted therapy neoplasm pathology personalized medicine procedures Antineoplastic Agents Biomarkers, Tumor Drug Approval Humans Molecular Targeted Therapy Neoplasms Precision Medicine Receptor, ErbB-2 |
Type | Other |
Pagination | 673-675 |
Issue Number | 4 |
Volume Number | 24 |
Files in this item
This item appears in the following Collection(s)
-
Medicine Research [1412 items ]